RNAi related Press Releases
Alnylam Pharmaceuticals Earns $20 Million Payment from Takeda Pharmaceutical Co. Ltd.
Alnylam Pharmaceuticals Earns $20 Million Payment from Takeda Pharmaceutical Co. Ltd. October 7, 2008 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading... Read more...
PRESS RELEASE: Amarin Corporation to Buy Privately Held Ester Neurosciences for up to $17M
Amarin Corporation to Buy Privately Held Ester Neurosciences for up to $17M LONDON, December 5 -- Amarin Corporation today announced that the Company has: - Signed an agreement to acquire Ester... Read more...
PRESS RELEASE: Nastech Pharmaceutical Company to Establish Subsidiary, MDRNA
Nastech Pharmaceutical Company to Establish Subsidiary, MDRNA, as an Independent Company to Focus on the Development of RNA-Based Therapeutics BOTHELL, Wash., Nov. 13 -- Nastech Pharmaceutical... Read more...
PRESS RELEASE: Merck Licenses SNALP Technology from Protiva
MERCK LICENSES SNALP TECHNOLOGY FROM PROTIVA Protiva to Receive One-Time Payment with Potential Milestone and Royalty Payments as Part of Broader Agreement VANCOUVER, BRITISH COLUMBIA--(October 16,... Read more...
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
